Virtual Library

Start Your Search

Ryoichi Nakanishi



Author of

  • +

    EP1.15 - Thymoma/Other Thoracic Malignancies (ID 205)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Thymoma/Other Thoracic Malignancies
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.15-07 - A Mutational Analysis of Epidermal Growth Factor Receptor Pathway Genes in Thymic Carcinoma (Now Available) (ID 1286)

      08:00 - 18:00  |  Author(s): Ryoichi Nakanishi

      • Abstract
      • Slides

      Background

      Thymic carcinoma is rare and usually has a fatal outcome. In many malignancies, gene mutations in the epidermal growth factor receptor (EGFR) signaling pathway are important for predicting a patient’s prognosis and as targets in molecular-targeted therapy. However, these mutations have not been well analyzed in thymic carcinoma.

      Method

      We examined a large cohort of thymic carcinoma and looked for gene mutations in the EGFR pathway genes; RAS family, EGFR, PIK3CA, AKT1, and BRAF using a highly sensitive single-base extension multiplex assay, SNaPshot assay.

      Result

      Among 54 thymic carcinoma cases, 13 (24.1%) showed 14 mutations: RAS family mutations in 10 cases (18.5%; KRAS in 6 [11.1%], HRAS in 3 [5.6%], and NRAS in 1 [1.9%]), EGFR in 2 (3.7%), PIK3CA in 1 (1.9%), AKT1 in 1 (1.9%), and BRAF in 0. All of these mutations were of the missense type, and mutations were mutually exclusive in all cases except in one case that harbored HRAS and AKT1 mutations. A prognostic analysis focusing on squamous cell-type thymic carcinoma cases (n=44, 9 mutation-positive cases) showed that the overall survival (OS) was significantly shorter in patients with EGFR pathway mutations than in those without in a univariate analysis (median OS time, 22 months vs. 102 months; p=0.0173) (Figure 1). Subsequently, EGFR pathway mutations were selected as an independent factor for a poor overall survival (p=0.0389).figure 1.gif

      Conclusion

      In the present study, gene mutations in the EGFR pathway in thymic carcinoma were found more frequently than in previous studies. Gene mutations in the EGFR pathway may be associated with a poor prognosis in thymic carcinoma patients. Therapeutic significance of the gene mutations in thymic carcinoma should be further clarified.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.